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Abstract
Alternative graft sources, [umbilical cord blood (UCB), matched unrelated donors (MUD), or 
mismatched unrelated donors (MMUD)] enable patients without a matched sibling donor to 
receive potentially curative hematopoietic cell transplantation (HCT). Retrospective studies 
demonstrate comparable outcomes among different graft sources. However, the risk and types of 
infections have not been compared among graft sources. Such information may influence the 
choice of a particular graft source. We compared the incidence of bacterial, viral, and fungal 
infections in 1,781 adults with acute leukemia who received alternative donor HCT (UCB = 568, 
MUD = 930, MMUD = 283) between 2008 and 2011. The incidence of bacterial infection at one 
year was 72%, 59%, and 65% (p<0.0001) for UCB, MUD and MMUD, respectively. Incidence of 
viral infection at one year was 68%, 45%, 53% (p<0.0001) for UCB, MUD, and MMUD 
respectively. In multivariable analysis, bacterial, fungal, and viral infections were more common 
after either UCB or MMUD than MUD, (p<0.0001). Bacterial and viral, but not fungal, infections 
were more common after UCB than MMUD (p=0.0009 and <0.0001, respectively). The presence 
of viral infection was not associated with an increased mortality. Overall survival (OS) was 
comparable among UCB and MMUD patients with Karnofsky performance status (KPS) ≥90%, 
but was inferior for UCB for patients with KPS < 90%. Bacterial and fungal infections were 
associated with poorer OS. Future strategies focusing on infection prevention and treatment are 
indicated to improve HCT outcomes.
Keywords
umbilical cord blood; leukemia; infection
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INTRODUCTION
Umbilical cord blood (UCB) is an important hematopoietic cell source for patients without 
matched related (MRD) or matched unrelated donors (MUD). Several studies have shown 
comparable survival after hematopoietic cell transplantation (HCT) using either matched 
(MUD) or mismatched unrelated (MMUD) donors or UCB transplantation (UCBT)1,2,3. In 
general, engraftment is delayed in UCBT, but the incidence of chronic graft versus host 
disease (GvHD) is less. To overcome low cell dose in UCBT, multiple investigators have 
used double UCBT in adults following either myeloablative (MA) or reduced intensity 
conditioning (RIC) regimens4,5,6,7. Despite these advances, poor immune reconstitution 
remains a significant problem after UCBT8.
Several studies have reported a high rate of viral infection after UCBT. The incidence of 
human herpes virus (HHV)-6 infection ranges from 0–10% after MUD and 5 to 21% after 
UCBT9. High viral infection risk after UCBT is likely related to the delayed immune 
reconstitution post-transplant10, 11,12,13. Fungal infections remain an important cause of 
morbidity and mortality after allogeneic HCT, particularly alternative donor HCT. The 
incidence of invasive fungal infection (IFI) has been reported at 9% after allogeneic HCT; 
some studies show an increase in fungal infection with matched unrelated donor compared 
to matched related donor.14,15,16. In a study of 1400 patients in China, mortality was over 
30% in patients with proven IFI15. Bacterial infections, especially after UCBT, are 
associated with high mortality. In 241 patients undergoing single UCBT, the incidence of 
bloodstream bacterial infection was 52% with a 12% mortality rate17.
The incidence, type, and risk factors for infection have not been formally compared in a 
large data set among MUD, MMUD, and UCBT. In this study, we seek to compare the 
incidence and type (fungal, viral, bacterial) of infections among transplant patients with 
acute leukemia that received UCB, MUD, and MMUD HCT. As infections are a significant 
cause of morbidity, mortality and resource utilization following HCT, data from this study 
may enable transplant physicians to better select the optimal donor source and to utilize 
more effective infection prevention and treatment strategies.
PATIENTS AND METHODS
Transplant registry
Data were obtained from the CIBMTR, a research affiliate of the International Bone Marrow 
Transplant Registry, Autologous Blood and Marrow Transplant Registry, and the National 
Marrow Donor Program (NMDP) established in 2004. It comprises a voluntary working 
group of more than 450 transplantation centers worldwide that contribute data on 
consecutive allogeneic and autologous HCT procedures to a statistical center at the Medical 
College of Wisconsin in Milwaukee and the NMDP Coordinating Center in Minneapolis. 
Participating centers report longitudinal data on all transplants and compliance is monitored 
by on-site audits. Transplant essential data, collected for consented patients participating in 
CIBMTR data collection, include demographic, disease type and stage, survival, relapse, 
graft type, the presence of GVHD, and cause of death data. A subset of CIBMTR 
participants are selected for comprehensive research level data collection by weighted 
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randomization. Observational studies conducted by the CIBMTR are performed in 
compliance with all applicable federal regulations pertaining to the protection of human 
research participants. Protected health information used in the performance of such research 
is collected and maintained in CIBMTR’s capacity as a Public Health Authority under the 
Health Insurance Portability and Accountability Act Privacy Rule. Studies conducted by the 
CIBMTR are performed under guidance and review of the Institutional Review Board of the 
National Marrow Donor Program.
Patients
The study population consists of patients ≥16 years with acute leukemia in first or second 
complete remission (CR) receiving transplant with a single or double unrelated UCBT, a 
MUD, or a single antigen/allele MMUD who were reported to the CIBMTR between 2008 
and 2011. First HCTs, receiving either myeloablative (MA) or non-myeloablative/reduced 
intensity conditioning (NMA/RIC) regimens were included. Patients receiving ex-vivo T-cell 
depletion, CD34 selection, or post-transplant cyclophosphamide were excluded. Due to 
small sample size, patients receiving haploidentical HCT were excluded.
Infection data
Infections are reported to the CIBMTR using an organism code and site code. There are no 
data provided to assess infection prophylaxis, treatment, diagnostic criteria utilized by the 
center, or infection severity. Centers are instructed to report clinically significant infections 
with both on-line and in-person education regarding appropriate reporting. Data are 
reviewed by clinicians to assess appropriateness for inclusion in analyses. For yeast 
infections, sites were limited to lower respiratory infections, blood stream infections, and 
visceral organ involvement. Other fungal infections were included as reported by the center. 
Viral data excluded from analysis were suspected or “other virus” infection in the lips, 
nasopharynx/upper airway, feces, or skin. Bacterial data excluded were suspected bacterial 
infection in the oral cavity, lips, feces, nasopharynx/upper airway, and skin; H. pylori; 
vancomycin-resistant Enterococcus in the GI tract not specified, feces, genital area, skin not 
specified; E. coli or “other bacteria” in the genital tract; coagulase negative Staphylococcus 
in the oral cavity, nasopharynx/upper airway, GU tract not specified, or skin not specified; 
Enterococcus spp., Pseudomonas spp., or Streptococcus spp. in feces; and Streptococcus or 
Corynebacterium (non-diphtheroids) species on the skin.
Outcomes and study definitions
The primary objective of this study was to compare the incidence of bacterial, fungal, and 
viral infections at 100 days and one-year post transplantation, for alternative donor HCT. To 
account for multiple infectious episodes occurring in a single patient and adjusted for a 
period of time at risk, infection density was determined18. The infection density is: the 
infections per patient days of risk during the first year. A recurrent infection was standardly 
defined and incorporated once versus multiple times in the infection density calculation. The 
infection densities for gram-positive and gram-negative bacterial infections, cytomegalovirus 
(CMV), adenovirus (ADV), and Epstein-Barr virus (EBV) infections, and infection density 
of Aspergillus, non-aspergillus molds, and candida infections during the first year post-
transplant were calculated. Infection as primary or secondary cause of death by day 100 and 
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by 1 year was described. Secondary endpoints consisted of overall survival (OS) and relapse 
at 100 days and one year. All outcomes were assessed from the date of HCT. Death from any 
cause was considered an event. Surviving patients were censored at time of last follow-up.
Disease status was classified as CR1 or CR2 for leukemia patients.19,20,21. Preparative 
regimens were classified as MA or NMA/RIC according to standard definitions22,23.
Patient-, disease-, and transplant-related variables
The following patient-related variables were described: age, performance status, and pre-
transplant fungal infection. Disease-related variables included disease: acute myeloid 
leukemia (AML) or acute lymphoid leukemia (ALL), disease status and time from diagnosis 
to transplant. Transplant-related variables were as follows: (a) HLA matching: 4/6 vs 5/6 vs 
6/6 for single cord (n=106) and the combinations for both cord blood units (i.e., 4/6 + 4/6) 
for double cords (n=462); (b) Conditioning regimen intensity: (c) Total body radiation (TBI) 
in conditioning: yes versus no; (d) GvHD prophylaxis; (e) use and type of antithymocyte 
globulin (ATG): none versus horse versus rabbit; (f) Time to neutrophil and platelet 
engraftment; (g) Acute and chronic GvHD; (h) Use of intravenous gammaglobulin and 
growth factors; and (i) Donor/recipient CMV serostatus.
Statistical analysis
Patient-, disease- and transplant-related factors were compared between groups using the 
Chi-square test for categorical variables and the Wilcoxon two-sample test for continuous 
variables. Non-relapse mortality (NRM) was calculated using the cumulative incidence 
function with relapse as the competing event. The incidence of bacterial, fungal, and viral 
infection for the first infection event was determined using the cumulative incidence 
function with death and relapse as competing events. To account for multiple infections, the 
infection density was calculated for gram-positive bacteria, gram-negative bacteria, CMV, 
EBV, ADV, Aspergillus, non-Aspergillus molds, and Candida infections. The infection 
density was compared between groups using the Kruskal-Wallis test. Kaplan-Meier 
probabilities for OS were estimated.
Multivariable models for OS and leukemia free (LFS) survival, NRM, and the development 
of fungal, viral, and bacterial infections were calculated using the Cox model with 
examination of the proportional hazards assumption. If the proportional hazards assumption 
was violated, the variable was added as a time-dependent covariate. Variables analyzed (* 
denotes reference group) included donor source [MUD*, MMUD, UCB], age [16–30y*, 31 
– 50y, >50y], KPS [≥90%*, <90%], disease [AML*, ALL], disease status [CR1*, CR2], 
time from diagnosis to transplant [<5m*, 6–11m, ≥12m], ATG [no*, yes], conditioning 
intensity [myeloablative*, reduced/non-myeloablative], donor/recipient CMV serostatus 
[neg/neg*, any positive], G-CSF use post-transplant [no*, yes], acute GvHD as a time 
dependent co-variate occurring prior to infection onset [grade 0/1*, grade 2–4], chronic 
GvHD as a time dependent co-variate occurring prior to infection onset [no*, yes], year of 
transplant [2008–2009*, 2010–2011], pre-transplant fungal infection [no*, yes], and time 
from fungal infection to transplant. The stepwise selection procedure was used to select 
significant covariates. An interaction between the main effect and time to infection and 
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significant covariates was tested. In particular, time to infection was examined as a time-
dependent covariate for OS, NRM, and relapse.
RESULTS
Patient, Disease, and Transplant Characteristics
Table 1 outlines the patient, disease, and transplant characteristics. Five hundred and sixty-
eight (568) UCB from 109 centers, 930 MUD from 114 centers and 283 MMUD patients 
were included from 83 centers. Single and double UCB patients were combined for analysis, 
due to patient numbers and similar outcomes. 106 patients received a single cord, the 
majority receiving a unit with at least one mismatch [HLA match 6/6 = 17 (16%), 5/6 = 38 
(36%), 4/6 = 51 (48%)]. Only 4% of the double UCBT patients received two 6/6 HLA 
matched units. The majority of patients in the MUD and MMUD groups received peripheral 
blood stem cells (MUD 82%, MMUD 81%). MUD and MMUD patients were more likely to 
be older, have a lower performance status, have AML, and be transplanted in CR1 than UCB 
patients. ATG was used most commonly in the MMUD patients. Table 2 describes the post-
transplant variables of engraftment and development of acute and chronic GvHD. The 
median follow-up of survivors was 46 months, 58 months and 56 months for UCBT, MUD, 
and MMUD recipients, respectively.
Effect of Donor Source on Infections and Post-Transplant Outcomes
We studied the effect of donor source on the incidence of bacterial, fungal, and viral 
infections, and on post-transplant outcomes, as shown in Table 3. Relapse was comparable 
among the donor sources. Non-relapse mortality (NRM) was comparable between UCB 
(33%) and MMUD (27%) patients and was higher than in MUD (14%) recipients, 
(p<0.0001).
The incidence at one year for any bacterial infection was 72% for UCB, 59% for MUD and 
65% for MMUD (UCB vs MMUD p=0.04). Gram negative infections were also more 
frequent following UCB (UCB 28% vs MUD 21% vs MMUD 23%; p=0.013). Gram 
positive bacteremia represented approximately 70% of the gram positive infections for all 
the graft sources; gram negative bacteremia represented approximately 60% of the gram 
negative infections for all of the graft sources. Bacterial urine infections were approximately 
16% of the bacterial infections for all of the graft sources. One-year incidence of fungal 
infections was 18% for UCBT, 10% for MUD, and 16% for MMUD (UCB vs MMUD, p = 
0.42). Focusing on lung/lower respiratory tract, Aspergillus was reported in 48%, 46%, and 
25% of the lung infections following UCB, MUD and MMUD respectively. Candida was 
reported in 24% of 32 pulmonary infections for UCB patients, 35% of 48 pulmonary 
infections in MUD, and 24% of 25 pulmonary infections in MMUD. Candidemia was seen 
in a similar percentage of candida infections across the graft sources. For viral infections, the 
incidence at one year was 68% for UCBT, 45% for MUD, and 53% for MMUD (UCB vs 
MMUD p<0.0001).
We investigated bacterial, viral, or fungal infection as the primary or secondary cause of 
death. For those patients (n= 264) who died, infection as the primary or secondary cause of 
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death by Day 100 was similar across graft sources. By 1 year post-HCT 673 patients [UCB 
= 277 (49%), MUD = 284 (31%), MMUD = 112 (40%)] had died with infection reported as 
a primary or secondary cause of death greatest in UCB (UCB 39%, MUD 29%, MMUD 
34%; p = 0.002).
Infection Density
Infection density compares the normalized rate of infection of a specific type occurring over 
a specific interval and accounts for multiple infections. Patients receiving UCB had a higher 
rate of CMV and ADV infections (p>0.001); EBV infections occurred more frequently in 
MMUD recipients (p = 0.021) (Figure 1A). CMV disease represented about 5% of CMV 
infection in all of the graft sources. Adenovirus pneumonitis was rare and was reported in no 
UCBT patients, 2 patients with MUD, and 1 patient with MMUD. Gram-positive bacterial 
infections were more common in MMUD and UCB compared to MUD recipients (p 
<0.001). Infections with gram-negative bacteria were more frequent in the UCB recipients, 
compared to MUD and MMUD (p = 0.003) (Figure 1B). Mold infections with either 
Aspergillus spp or other molds occurred at similar rates and were uncommon regardless of 
graft source. Candida spp. infections were rare and also similar regardless of graft source 
(Figure 1C).
Multivariate Analysis of Infections among the Graft Sources
Table 4 provides the results of a multivariate analysis comparing infections among the 
different graft sources. Bacterial infections were 1.2-fold more common in MMUD (p = 
0.029) and 1.6-fold more in UCB (<0.001) than MUD recipients. Similarly, MMUD 
recipients were almost 1.4-fold (p = 0.04) and UCB recipients 1.7-fold (p <0.0001) as likely 
to develop a fungal infection compared to MUD. However, there was no difference for the 
likelihood of fungal infection between MMUD and UCB recipients. Viral infections were 
notably higher in the UCB group with 2.3-fold higher risk compared to MUD (p<0.0001). 
MMUD recipients had a 1.3-fold higher risk compared to MUD (p = 0.0067) recipients but 
were 45% less likely than the UCB recipients to develop a viral infection (p<0.0001).
Additional risk factors identified to increase the risk of bacterial infections include 
development of acute or chronic GvHD and transplant between 2008 and 2009. In the first 3 
months after transplant, patients receiving NMA/RIC were 42% less likely to have a 
bacterial infection. However, this benefit was lost after 3 months from transplant. Viral 
infections were also less likely following NMA/RIC regimens but this persisted throughout 
the post-transplant period. Use of ATG and donor or recipient positive CMV serostatus also 
increased the risk of viral infection. Development of acute or chronic GVHD also increased 
the risk of viral infection. No other factors were identified to increase the risk of fungal 
infections. Disease status (CR 1 vs CR 2) had no impact on the incidence of bacterial, viral, 
or fungal infection.
Impact of Graft Sources and Infection on post-Transplant Outcomes
For OS and LFS, multivariable analysis found that graft source, bacterial and fungal 
infection, and age were significant factors (Table 5). Graft source affected OS and LFS for 
patients with a KPS < 90%. (Figure 2). For patients with KPS <90%, UCB recipients had 
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inferior OS and LFS compared with either MUD [OS: p <0.0001; LFS: p <0.0001] or 
MMUD sources [OS: p=0.010; LFS: p=0.047]. LFS was comparable among UCB, MMUD, 
and MUD patients with a KPS ≥ 90%. OS was superior for MUD patients than MMUD or 
UCB for patients with KPS > 90%; OS was similar for UCB and MMUD for patients with 
KPS >90% (Figure 3). The development of a bacterial infection was associated with a 2.45-
fold higher risk of death from any cause (p<0.0001). Fungal infections also negatively 
impacted OS and LFS [OS: RR 3.0, p<0.0001; LFS: RR 2.46, p<0.0001], while viral 
infections did not affect OS or LFS.
Several factors, including graft source, influenced NRM. Specifically, recipients of MMUD 
had a 1.37-fold higher risk (p<0.001) and UCB a 1.45-fold higher risk (p<0.001) of death in 
remission compared with MUD. Notably, there was no difference between recipients of 
MMUD and UCB. In addition, the development of bacterial infection [RR: 3.17, p<0.0001], 
fungal infection [RR: 3.97, p<0.0001], and viral infection [RR: 1.24, p = 0.028] were all 
independent risk factors for higher NRM. The only independent predictor of relapse was the 
use of NMA/RIC conditioning.
DISCUSSION
In this study, one of the first of its kind, we compare bacterial, fungal, and viral infections 
among different donor graft sources, studying single and double UCBT, and 8/8 and 7/8 
HLA-matched unrelated donor transplants. Matched sibling donor HCT was not included as 
the clinical decision is often choosing between UCBT and MUD or MMUD HCT. Since 
many retrospective studies have shown similar survival among these different graft sources, 
we focused on infections to help determine the appropriate graft source for each patient and 
to help design appropriate preventative strategies1,2,3, 24,25. The incidence of bacterial, 
fungal, and viral infections are high (68%, 45%, and 53% at one year for UCB, MUD, and 
MMUD respectively) after alternative donor transplant. Over 50% of patients developed 
bacterial infections at one year. In multivariable analysis, bacterial, fungal, and viral 
infections were more common after UCB than MUD (p <0.001, 0.001, and <0.001) 
respectively. Bacterial, fungal, and viral infections were more common after MMUD than 
MUD (p=0.0295, 0.041, and 0.0067 respectively). Bacterial and viral infections were more 
common after UCB than MMUD (p=0.0009 and <0.0001 respectively), perhaps due to 
slower engraftment and delayed immune recovery. However, there was no difference in 
fungal infections based on graft source. Bacterial and fungal infections were also associated 
with poorer survival. Surprisingly, the presence of a viral infection did not affect overall 
survival.
Bacterial infections have been studied in the early and late phases after HCT in 172 
patients26. In this study, there were 100 episodes of blood-stream infections (BSI) in the pre-
engraftment period and 89 episodes post engraftment. GvHD and steroids were predictors 
for late-onset bacteremia; graft source was not well studied. Kikuchi and colleagues reported 
on 122 UCB, 51 MRD, 26 haploidentical, 98 MUD, and 24 MMUD patients. Pre-
engraftment BSI occurred in 39% of patients and post-engraftment BSI in 17% of patients; 
graft source did not affect this incidence27.
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Strategies to prevent bacterial infection include prophylactic antibiotics such as quinolones. 
A meta-analysis of 17 trials and 1453 patients concluded that antibiotic prophylaxis reduced 
the incidence of fever and bacteremia, but did not impact all-cause or infection-related 
mortality28. C. difficile (C. Diff) was not a focus of our study, but other investigators have 
reported similar incidence and recovery from C. Diff infections after UCBT, MRD, or 
MUD29.
Viral infections have been analyzed extensively, especially after UCBT. Our study focused 
on CMV, ADV and EBV because these viral infections are significant causes of morbidity 
and mortality after allogeneic HCT. EBV-associated post-transplant lymphoproliferative 
disorder (PTLD) has been seen in up to 13% of patients receiving RIC and 3% for MA 
UCBT recipients30.
Our study showed a higher incidence of viral infection with the use of either horse or rabbit 
ATG. However, single center studies have demonstrated a 30% incidence of viral infections 
even without ATG.31 CMV reactivation is quite common after UCBT, and clearance of 
CMV and survival is associated with de novo production of thymic derived T cells10. Due to 
the nature of the registry data, we were not able to evaluate the impact of strategies to reduce 
CMV reactivation, such as the use of IV ganciclovir during conditioning32. Delayed immune 
reconstitution after alternative donor HCT, particularly after UCBT, may explain the high 
risk of infection. A comparison of immune recovery after double UCBT and HLA-matched 
MUD revealed delay in recovery of naive (CD45RO-) and memory (CD45RO+) CD 4 T 
cells, CD8 T cells, and regulatory (CD4+CD25+) T cells, which correlates with the 
increased viral infection in the early post-transplant period8. A delayed time to recovery of 
thymopoiesis has been reported in recipients of UCBT compared to other graft 
sources11,33,34.
Fungal infections are an important cause of morbidity and mortality after HCT. The Gruppo 
Italiano Trapianto Midollo Osseo (GITMO) studied 1,858 patients undergoing allogeneic 
HCT35. Incidence of proven/probable invasive fungal disease was 8.8% at one year. Risk 
factors for developing invasive fungal disease were MUD or UCBT, active leukemia, prior 
fungal infection, and GvHD. In contrast, a study from Massachusetts General Hospital did 
not show a correlation between prior fungal infection and invasive fungal disease14. Parody 
and colleagues reported a higher incidence of invasive aspergillosis after UCBT but no 
difference in mortality compared to MUD36.
Although the primary endpoint was infection, LFS and OS were also analyzed in this study. 
OS was comparable among MUD, MMUD, and UCB for patients with a Karnofsky 
performance status (KPS) of 90% or greater; OS was inferior for UCB for patients with KPS 
< 90%. Therefore, when multiple graft sources are available, patients with poor performance 
status may have better outcomes with a MUD or MMUD HCT. Thus, these data may be 
used to help identify factors that may be modified, such as graft source, in the treatment 
approach. Many variables are used in the selection of the appropriate graft and information 
on infections and performance status may need to be considered along with other factors. 
Recently, the CIBMTR and Eurocord compared survivals for older patients with acute 
myeloid leukemia in CR 1 undergoing alternative donor transplant2. NRM was higher for 
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patients receiving UCBT or 7/8 MUD HCT. Three-year OS was 43% in 8/8 matched MUD, 
30% in UCBT (p=0.002) and 37% in 7/8 MUD (p=NS compared to UCB).
The study is limited by several factors. As with all registry studies, patients were treated in 
many centers with a variety of conditioning regimens, GvHD prophylactic treatments, and 
supportive care protocols. Furthermore, infections determined clinically significant are 
reported but there remains lack of data regarding diagnostic, prevention and treatment 
criteria. Therefore, this analysis is considered a high level overview and many important 
details regarding infection specifics and impact of immune reconstitution at the time of the 
infection cannot be addressed. Although parallel Phase II studies showed comparable OS 
between haploidentical HCT and UCBT, there were not enough haploidentical patients 
reported to the CIBMTR during the study period to include in this study37,38. Future studies 
will investigate infections after haploidentical transplant.
Clearly, better prevention and treatment of infection are needed to decrease the infection 
related mortality after alternative donor transplant. Strategies might include improved 
GVHD prophylaxis, new antifungal drugs or the use of ganciclovir before transplant as 
pioneered by the Seattle group32. Bacigalupo and colleagues have implemented the use of 
rituximab early after UCBT to decrease the incidence of EBV-related PTLD, even when 
high doses of ATG are given39. For patients that develop serious viral infection, an exciting 
new strategy is the use of either donor-derived or third party trivirus-directed cytotoxic T 
cells40. Use of these and other novel techniques may reduce the incidence of infection after 
UCBT or MMUD so that infection rates are comparable after all graft sources. The optimal 
donor source will need to be determined in a prospective trial. A randomized prospective 
trial comparing UCBT versus haploidentical is underway in the BMT Clinical Trials 
Network.
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Highlights
• Bacterial and viral, but not fungal, infections are more common after 
UCBT than MMUD.
• Bacterial and fungal, but not viral, infections were associated with 
poorer survival.
• Overall survival is comparable among graft sources if performance 
status is ≥90%.
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Figure 1. 
Infection density for specific viral (A), bacterial (B), and fungal (C) infections by graft 
source
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Figure 2. 
Univariate curves for leukemia free survival by graft source for patients based on Karnofsky 
score ≥ 90% (A) and <90% (B).
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Figure 3. 
Univariate curves for Overall Survival by graft source for patients based on Karnofsky score 
≥ 90% (A) and <90% (B).
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Table 2
Description of pertinent post-transplant event variables included in the multivariable Cox model
Variable MUDN=930
MMUD
N=283
UCB
N=568
Neutrophil engraftment,
median (range), days
MAC 14 (1–73) 14(3–35) 23 (1 – 80)
NMA/RIC 14 (<1 −81) 13(1 −26) 15 (<1 −50)
Acute GVHD
Grade 0 −1 516(56%) 141 (50%) 288(51%)
Grade 2 274 (29%) 89(31%) 194(34%)
Grade 3–4 140(15%) 53(19%) 86(15%)
Onset acute GVHD,
Median (range), days 28(7–176) 26(8–119) 29(7–178)
Chronic GVHD, any severity,
Yes
508 (55%) 149(53%) 187(33%)
Onset chronic GVHD,
Median (range), months 6 (2 – 75) 6 (2 – 47) 5 (2 – 53)
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Table 3
Univariate outcomes and cumulative incidence of infection at 1 year by donor source.
MUD
% (95% CI)
MMUD*
% (95% CI)
UCB*
% (95% CI)
p-value
Transplant Outcomes
OS 69%
(66 – 72%)
60%
(54 – 66%)
51%
(47 – 55%)
<0.0001
LFS 56%
(56 – 72%)
49%
(43 – 54%)
44%
(40 – 48%)
<0.0001
Relapse 27%
(24 – 30%)
25%
(20 – 30%)
24%
(21 – 28%)
0.43
NRM 14%
(12–16%)
27%
(22 – 32%)
33%
(29 – 36%)
<0.0001
Infection Incidence
Bacterial 59%
(57 – 64%)
65%
(59 – 70%)
72%
(68 – 76%)
<0.0001
Viral 45%
(42 – 48%)
53%
(47 – 59%)
68%
(64 – 72%)
<0.0001
Fungal 10%
(8–12%)
16%
(12–20%)
18%
15–21%)
0.0001
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